Q3 2024 EPS Estimates for Allogene Therapeutics, Inc. Raised by HC Wainwright (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities researchers at HC Wainwright lifted their Q3 2024 EPS estimates for Allogene Therapeutics in a report released on Thursday, August 15th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.30) per share for the quarter, up from their prior estimate of ($0.33). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q4 2024 earnings at ($0.32) EPS, FY2024 earnings at ($1.32) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.39) EPS.

ALLO has been the subject of several other reports. Oppenheimer began coverage on Allogene Therapeutics in a report on Thursday, August 8th. They issued an “outperform” rating and a $11.00 price objective for the company. Piper Sandler began coverage on Allogene Therapeutics in a report on Friday, May 31st. They issued an “overweight” rating and a $11.00 price objective for the company. Stifel Nicolaus lifted their price objective on Allogene Therapeutics from $4.40 to $4.60 and gave the company a “hold” rating in a report on Tuesday, May 14th. Truist Financial reiterated a “buy” rating and issued a $14.00 target price (down from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Finally, Canaccord Genuity Group reduced their target price on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Allogene Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $9.96.

Allogene Therapeutics Price Performance

ALLO stock opened at $2.64 on Monday. The business has a 50-day moving average price of $2.57 and a 200 day moving average price of $3.35. The company has a market capitalization of $551.76 million, a P/E ratio of -1.47 and a beta of 0.85. Allogene Therapeutics has a 1-year low of $2.01 and a 1-year high of $5.78.

Insider Transactions at Allogene Therapeutics

In other news, Director Franz B. Humer sold 11,200 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $2.34, for a total transaction of $26,208.00. Following the completion of the transaction, the director now directly owns 255,253 shares of the company’s stock, valued at approximately $597,292.02. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 24.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ALLO. Arizona State Retirement System raised its stake in Allogene Therapeutics by 22.2% in the 4th quarter. Arizona State Retirement System now owns 30,458 shares of the company’s stock valued at $98,000 after purchasing an additional 5,543 shares during the last quarter. Vontobel Holding Ltd. increased its stake in shares of Allogene Therapeutics by 28.6% in the 4th quarter. Vontobel Holding Ltd. now owns 18,000 shares of the company’s stock worth $58,000 after acquiring an additional 4,000 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Allogene Therapeutics by 55.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,551 shares of the company’s stock worth $72,000 after acquiring an additional 8,037 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in shares of Allogene Therapeutics by 116.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 32,498 shares of the company’s stock worth $104,000 after acquiring an additional 17,471 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Allogene Therapeutics by 23.1% in the 4th quarter. Victory Capital Management Inc. now owns 14,283 shares of the company’s stock worth $46,000 after acquiring an additional 2,680 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).